Celyad Oncology S.A.
CYAD
株式のランク
#31685
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
株価
$0.24909259
時価総額
$11.77M
変化（1日）
1.94%
変化（1年）
-47.00%
国
BE
取引 Celyad Oncology S.A. (CYAD)
カテゴリー
Healthcare
Celyad Oncology S.A.（CYAD）のP/S比率
2026 時点のP/S比率 TTM: 0
Celyad Oncology S.A. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0 です。2026 年末時点でのP/S比率は 0 でした。
Celyad Oncology S.A. の P/S 比率の履歴（2026 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
